Press release
Investigation announced for Investors in Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX)
An investigation on behalf of investors in Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares over potential wrongdoing at Kiora Ph
Investors who purchased shares of Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Kiora Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
Waltham, MA based Kiora Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. Kiora Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $2.68 million in 2019 to $0.012 million in 2020, and that its Net Loss increased from $7.09 million in 2019 to $8.17 million in 2020.
Shares of Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) declined from over $12 per share in late 2019 to as low as $1.44 per share in August 2021.
On November 17, 2021, NASDAQ: KPRX shares closed at $1.50 per share.
Those who purchased shares of Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) here
News-ID: 2465974 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Kiora
Retinitis Pigmentosa Treatment Market Driven by Gene Therapy Progress and Increa …
Retinitis Pigmentosa Treatment Market size reached US$ 5.72 Billion in 2024 and is expected to reach US$ 11.13 Billion by 2033, growing at a CAGR of 7.7% during the forecast period 2025-2033.
Retinitis Pigmentosa Treatment Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With a focus on emerging drug technologies, evolving treatment paradigms, and…
Retinitis Pigmentosa Treatment Market Industry Growth and Demand through 2024-20 …
Global Retinitis Pigmentosa Treatment Market reached at a CAGR during the forecast period 2024-2031.
The Retinitis Pigmentosa Treatment market report provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Leveraging a combination of qualitative and quantitative research methods, the company offers comprehensive reports that help…
Retinitis Pigmentosa Treatment Market Report: Detailed Insights and Key Players …
The Retinitis Pigmentosa Treatment Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Retinitis Pigmentosa Treatment market report is an essential resource for market participants who are looking to gain a comprehensive understanding of the market and identify opportunities for…
Autoimmune Uveitis Market Report Outlines Revenue Share, SWOT Analysis and Playe …
The Autoimmune Uveitis Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/autoimmune-uveitis-market
What is the projected…
Retinitis Pigmentosa Treatment Market Report Analysis, Research Studies |Spark T …
DataM Intelligence has published a new research report on "Retinitis Pigmentosa Treatment Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF…
Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX) …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc.
Investors who purchased shares of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. officers and…
